Project/Area Number |
23590198
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Showa University (2013) Saitama Medical University (2011-2012) |
Principal Investigator |
FUJITA Ken-ichi 昭和大学, 腫瘍分子生物学研究所, 准教授 (60281820)
|
Co-Investigator(Renkei-kenkyūsha) |
SASAKI Yasutsuna 昭和大学, 医学部, 教授 (20235279)
OKAZAKI Yasushi 埼玉医科大学, 医学部, 教授 (80280733)
KATO Yukio 金沢大学, 薬学系, 教授 (30251440)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
Keywords | SN-38 / 排泄遅延 / 腎機能低下 / 尿毒素 / OATP1B1 / 発現低下 / 肝消失型抗がん薬 / 蛋白結合 / 肝消失型 / 排出遅延 / 腎機能 / 尿毒症物質 / 腎不全 / イリノテカン / 体内動態 / トランスポーター / UGT1A1 |
Research Abstract |
We have shown for the first time that uremic toxins such as CMPF inhibit SN-38 uptake in human hepatocytes at clinically relevant concentrations. OATP1B1 is a major contributor to the saturable uptake of SN-38 in human hepatocytes. The gene expression of SLCO1B1 was down-regulated by uremic plasma. The inhibition by uremic toxins of OATP1B1-mediated SN-38 uptake and the down-regulated SLCO1B1 gene expressions may be part of the mechanisms causing the delay of SN-38 elimination observed in patients with severe renal dysfunction.
|